Fig. 1

N6-methyladnosine level was substantially increased in both adenoma and colorectal carcinoma and associated with poor prognosis. N6-methyladnosine (m6A) levels in both adenoma and colorectal carcinoma (CRC) were assayed through (a) Methylation quantification assay, b Immunohistochemistry (IHC), and (c) Immunofluorescence. d Representative images of IHC staining for m6A level as obtained from 201 CRC tissues and 159 normal tissues; e IHC staining scores of m6A; f Kaplan–Meier overall survival analysis of m6A expression in patients with CRC. Data are presented as means ± standard deviations (SDs). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001